Jiskoot W - Search Results

1

CD39 identifies a microenvironment-specific anti-inflammatory CD8⁺ T-cell population in atherosclerotic lesions.

van Duijn J, van Elsas M, Benne N, Depuydt M, Wezel A, Smeets H, Bot I, Jiskoot W, Kuiper J, Slütter B. van Duijn J, et al. Among authors: jiskoot w. Atherosclerosis. 2019 Jun;285:71-78. doi: 10.1016/j.atherosclerosis.2019.04.217. Epub 2019 Apr 11. Atherosclerosis. 2019. PMID: 31048101 Free article.

2

Rational design of nasal vaccines.

Slütter B, Hagenaars N, Jiskoot W. Slütter B, et al. Among authors: jiskoot w. J Drug Target. 2008 Jan;16(1):1-17. doi: 10.1080/10611860701637966. J Drug Target. 2008. PMID: 18172815 Review.

3

Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination.

Slütter B, Plapied L, Fievez V, Sande MA, des Rieux A, Schneider YJ, Van Riet E, Jiskoot W, Préat V. Slütter B, et al. Among authors: jiskoot w. J Control Release. 2009 Sep 1;138(2):113-21. doi: 10.1016/j.jconrel.2009.05.011. Epub 2009 May 13. J Control Release. 2009. PMID: 19445980

4

Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations.

Bal SM, Slütter B, van Riet E, Kruithof AC, Ding Z, Kersten GF, Jiskoot W, Bouwstra JA. Bal SM, et al. Among authors: jiskoot w. J Control Release. 2010 Mar 19;142(3):374-83. doi: 10.1016/j.jconrel.2009.11.018. Epub 2009 Nov 22. J Control Release. 2010. PMID: 19932723

5

Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen.

Slütter B, Soema PC, Ding Z, Verheul R, Hennink W, Jiskoot W. Slütter B, et al. Among authors: jiskoot w. J Control Release. 2010 Apr 19;143(2):207-14. doi: 10.1016/j.jconrel.2010.01.007. Epub 2010 Jan 13. J Control Release. 2010. PMID: 20074597

6

Dual role of CpG as immune modulator and physical crosslinker in ovalbumin loaded N-trimethyl chitosan (TMC) nanoparticles for nasal vaccination.

Slütter B, Jiskoot W. Slütter B, et al. Among authors: jiskoot w. J Control Release. 2010 Nov 20;148(1):117-121. doi: 10.1016/j.jconrel.2010.06.009. Epub 2010 Jun 18. J Control Release. 2010. PMID: 20600405

7

Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.

Slütter B, Bal S, Keijzer C, Mallants R, Hagenaars N, Que I, Kaijzel E, van Eden W, Augustijns P, Löwik C, Bouwstra J, Broere F, Jiskoot W. Slütter B, et al. Among authors: jiskoot w. Vaccine. 2010 Aug 31;28(38):6282-91. doi: 10.1016/j.vaccine.2010.06.121. Epub 2010 Jul 16. Vaccine. 2010. PMID: 20638455

8

Antigen-adjuvant nanoconjugates for nasal vaccination: an improvement over the use of nanoparticles?

Slütter B, Bal SM, Que I, Kaijzel E, Löwik C, Bouwstra J, Jiskoot W. Slütter B, et al. Among authors: jiskoot w. Mol Pharm. 2010 Dec 6;7(6):2207-15. doi: 10.1021/mp100210g. Epub 2010 Nov 2. Mol Pharm. 2010. PMID: 21043518

9

Adjuvant effect of cationic liposomes and CpG depends on administration route.

Slütter B, Bal SM, Ding Z, Jiskoot W, Bouwstra JA. Slütter B, et al. Among authors: jiskoot w. J Control Release. 2011 Sep 5;154(2):123-30. doi: 10.1016/j.jconrel.2011.02.007. Epub 2011 Feb 21. J Control Release. 2011. PMID: 21315779

10

Small is beautiful: N-trimethyl chitosan-ovalbumin conjugates for microneedle-based transcutaneous immunisation.

Bal SM, Slütter B, Jiskoot W, Bouwstra JA. Bal SM, et al. Among authors: jiskoot w. Vaccine. 2011 May 23;29(23):4025-32. doi: 10.1016/j.vaccine.2011.03.039. Epub 2011 Mar 26. Vaccine. 2011. PMID: 21443959

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

328 results

Search Page

Filters